Diabetic retinopathy damages the blood vessels within the retinal tissue, causing them to leak fluid and distort vision.

NEW YORK, WASHINGTON, UNITED STATES, June 27, 2022 /EINPresswire.com/ -- The global diabetic retinopathy market size is expected to reach USD by 14.95 Billion 2028 at a CAGR of 7.10%, according to a new report by Reports and Data. Rising prevalence of chronic conditions such as diabetes, increasing cases of diabetic retinopathy among diabetic patients, and growing preferences for technologically advanced and minimally invasive procedures are among the major factors responsible for the growth of the global diabetic retinopathy market in the upcoming years. Booming geriatric population worldwide and their growing susceptibility to chronic diseases such as diabetes, cardiovascular disorders, and sleep disorders further boost market growth to a significant extent.

Diabetic retinopathy is a severe medical condition in which diabetes affects the eyes. The principal cause of diabetic retinopathy is damage to the blood vessels of the light-sensitive tissue of the retina. The most common symptoms of this condition include blurred vision, fluctuating vision, dark or empty areas in the vision, impaired color vision, and vision loss. Excessive amount of sugar in blood leads to the blockage of the tiny blood vessels of the retina and hamper blood supply. Mild-to-moderate cases of diabetic retinopathy may be treated with the help of effective diabetes management; however, advanced cases require laser treatment or surgical procedures.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1484

Competitive Landscape:

The report also covers SWOT examination and Porter’s Five Forces analysis to offer details about leading players. The key players in the market are focusing on developing new strategies such as mergers and acquisition, joint ventures, new product launches, agreements, and partnerships to retain their market position and expand their product base.

Leading companies operating in the market and profiled in the report include:

Bayer AG
Pfizer Inc
Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals Inc
Novartis AG
Valeant Pharmaceuticals International Inc
Abbott Laboratories Ltd
Alimera Sciences Inc
AmPio Pharmaceuticals Inc
Bausch & Lomb Inc
Boehringer Ingelheim GmbH
iCo Therapeutics Inc
Lupin Ltd
PAREXEL International Corp
Quark Pharmaceuticals Inc
Thrombogenic NV
Vitreoretinal Technologies Inc

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1484

Some Key Highlights in the Report:

Non-proliferative diabetic retinopathy segment is projected to register the highest CAGR of 7.5% over the forecast period. Rising prevalence of non-proliferative diabetic retinopathy among diabetic patients is one of the most vital factors driving this segment’s growth.

On the basis of management, the anti-VEGF segment dominated tin terms of revenue in 2020. The segment is expected to maintain its dominance throughout the forecast period, owing to increasing applications of anti-VEGF drugs including Eylea, Lucentis, Avastin, and Macugen in the treatment of mild-to-moderate cases of diabetic retinopathy is one of the key factors accountable for the growth of this segment.

Among the various distribution channels, the hospitals segment held the largest revenue share in the global diabetic retinopathy market in 2020. Increasing availability of diagnostic instruments in hospitals and pharmacies worldwide and growing number of treatment procedures for diabetic retinopathy bolster the growth of this segment.

The North America diabetic retinopathy market is the most dominant regional market in terms of revenue. Growing prevalence of diabetes, increasing use of anti-VEGF drugs including Avastin, Eylea, and Lucentis for diabetic retinopathy, rising patient awareness, and the presence of state-of-the-art healthcare infrastructure in North America are the primary factors accountable for the regional market growth. The Asia Pacific market is the fastest-growing regional market and is expected to display a robust CAGR of 8.3% over the forecast period.

Download Summary @ https://www.reportsanddata.com/download-summary-form/1484

For the purpose of this report, the global diabetic retinopathy market is segmented on the basis of type, disease form, management, distribution channel, and region:

Type (Revenue, USD Billion; 2020-2028)

Mild
Moderate
Severe

Disease Form (Revenue, USD Billion; 2020-2028)

Proliferative diabetic retinopathy
Non-proliferative diabetic retinopathy
Management (Revenue, USD Billion; 2020-2028)

Anti-VEGF
Intraocular steroid injection
Laser surgery
Vitrectomy

Distribution channel (Revenue, USD Billion; 2020-2028)

Eye clinics
Hospitals
Retail pharmacies
Online pharmacies
Ambulatory surgical centers
Other

Regional Outlook (Revenue, USD Billion; 2020-2028)

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Get TOC of this Report @ https://www.reportsanddata.com/report-detail/diabetic-retinopathy-market/toc

Thank you for reading our report. Get in touch with us to know more about the customization feature and our team with provide you the best suited report as per your need.

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W

Head of Business Development

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Reports and Data | Web: www.reportsanddata.com

Connect with us: Facebook| LinkedIn | Twitter

Tushar Rajput
Reports and Data
+ 12127101370
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.